Jensen-Munroe relapsed in 2023 and was told unfunded, $220,000-a-year drug daratumumab was her “best option”. Unable to afford that, last year she took the second option of a stem cell transplant.
Morningstar brands and products Company Portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback